Navigation Links
Jerome Wilson Joins PRA International's Late Phase Service Group
Date:10/27/2008

Dr. Jerome Wilson to serve as Lead Epidemiologist

RALEIGH, N.C., Oct. 27 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announced today the appointment of Dr. Jerome Wilson as Senior Medical Director of Late Phase Services. As the Lead Epidemiologist, Dr. Wilson is responsible for providing consulting services and developing post-marketing strategies for PRA clients.

PRA provides extensive Phase IV Post-Marketing services to pharmaceutical and biotech companies. The company has executed more than 150 Late Phase studies in 23 countries, recruiting over 126,000 patients in nearly 12,000 sites.

In addition to more than 15 years of scientific management experience in the pharmaceutical industry, Dr. Wilson served as Senior Interdisciplinary Scientist and Team Leader for Anthrax Therapeutics at the U.S. Department of Health and Human Services (HHS). For this role, the Biomedical Advanced Research and Development Authority Office recognized Dr. Wilson for distinguished service.

Dr. Wilson also served as Associate Director for Scientific Program Operations at the National Center on Minority Health and Health Disparities at the National Institutes of Health (NIH). He received the NIH Director's Award for his work on the Genome Wide Association Studies Policy Development Team.

Additionally, Dr. Wilson served as Senior Director/Team Leader of Outcomes Research at Pfizer and has held appointments at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute's Division of Cancer Epidemiology and Genetics, Howard University's Cancer Center, and Georgetown University's School of Medicine.

"We are pleased to add Dr. Wilson to our Late Phase Services team," commented Maria Harrison, Vice President of PRA Late Phase Services. "His expertise in the post-marketing field will serve as a tremendous benefit to our clients, and our team."

Dr. Wilson holds an A.B. Cum Laude from Dillard University, an A.M. from Harvard Medical School, and a Ph.D. from the University Of North Carolina School Of Public Health.

About PRA International

PRA International is a privately held, global Clinical Research Organization providing services through all phases of clinical development. We specialize in Oncology, CNS, respiratory/allergy diseases, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials in more than 60 countries on six continents through our global offices. PRA's therapeutic expertise, global reach, and project experience with local knowledge enable our project teams to deliver consistent, timely, and reliable service for our clients. PRA's Late Phase Services group supports global and regional post-approval studies with management in North America and Europe.

To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
2. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
3. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
4. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
5. Food and Beverage Giant Joins Kannapolis Research Center
6. Mark Sutherland Joins GenVault as Senior Vice President, Business Development
7. Chief Technology Officer Joins ACAMP
8. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
9. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
10. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
11. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):